NEWS HIGHLIGHTS
Published Studies Related to Albenza (Albendazole)
Efficacy and safety of single and double doses of ivermectin versus 7-day high dose albendazole for chronic strongyloidiasis. [2011.05.10]
BACKGROUND: Strongyloidiasis, caused by an intestinal helminth Strongyloides stercoralis, is common throughout the tropics. It remains an important health problem due to autoinfection, which may result in hyperinfection and disseminated infection in immunosuppressed patients, especially patients receiving chemotherapy or corticosteroid treatment...
Albendazole-praziquantel interaction in healthy volunteers: kinetic disposition, metabolism and enantioselectivity. [2011.04]
AIM: This study investigated the kinetic disposition, metabolism and enantioselectivity of albendazole (ABZ) and praziquantel (PZQ) administered alone and in combination to healthy volunteers... CONCLUSIONS: The pharmacokinetic interaction between ABZ and PZQ in healthy volunteers was demonstrated by the observation of increased plasma concentrations of ASON, both ASOX enantiomers and (-)-(R)-PZQ. Clinically, the combination of ABZ and PZQ may improve the therapeutic efficacy as a consequence of higher concentration of both active drugs. On the other hand, the magnitude of this elevation may represent an increased risk of side effects, requiring, certainly, reduction of the dosage. However, further studies are necessary to evaluate the efficacy and safety of this combination. (c) 2011 The Authors. British Journal of Clinical Pharmacology (c) 2011 The British Pharmacological Society.
A randomised controlled clinical trial on the safety of co-administration of albendazole, ivermectin and praziquantel in infected schoolchildren in Uganda. [2011.04]
Integrated chemotherapy of neglected tropical diseases (NTD) through mass drug administration given as a single dose would increase treatment coverage and cost-effectiveness...
Efficacy of single-dose and triple-dose albendazole and mebendazole against soil-transmitted helminths and Taenia spp.: a randomized controlled trial. [2011]
BACKGROUND: The control of soil-transmitted helminth (STH) infections currently relies on the large-scale administration of single-dose oral albendazole or mebendazole. However, these treatment regimens have limited efficacy against hookworm and Trichuris trichiura in terms of cure rates (CR), whereas fecal egg reduction rates (ERR) are generally high for all common STH species...
Albendazole and mebendazole administered alone or in combination with ivermectin against Trichuris trichiura: a randomized controlled trial. [2010.12.15]
BACKGROUND: Single-dose albendazole and mebendazole show limited efficacy in the treatment of trichuriasis. The combination of albendazole with ivermectin improves efficacy, but a mebendazole-ivermectin combination has not been previously investigated... CONCLUSIONS: Addition of ivermectin improves the therapeutic outcomes of both albendazole and mebendazole against T. trichiura and may be considered for use in soil-transmitted helminth control programs and individual patient management. TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN08336605.
Clinical Trials Related to Albenza (Albendazole)
Efficacy of Albendazole to Treat Intestinal Helminths and Its Effect on Gut Microflora [Recruiting]
Albendazole is a main anti-helminth, however there is a lack of data regarding its efficacy
in the school children population. The aim of this study is to evaluate the efficacy of the
albendazole one versus two and three doses, in school children infected with intestinal
helminth.
Effect of Albendazole Dose on Treatment of Lymphatic Filariasis [Recruiting]
This study is conducted in Kerala, India. It will determine whether a new treatment regimen
of albendazole and diethylcarbamazine (DEC) for lymphatic filariasis can eliminate the
disease more quickly than the standard regimen. Lymphatic filariasis is caused by infection
with very small parasitic worms that are spread by mosquitoes. The disease can cause
swelling of the arms, legs, breast and scrotum and can progress to permanent swelling of the
legs or arms called elephantiasis. The study will see if a higher and more frequent dose of
albendazole is better at clearing filarial worms from the blood than the current treatment.
Healthy people between 18 and 55 years of age who are in good health and who are infected
with filarial worms may be eligible for this study.
Participants undergo the following procedures:
3-day hospital stay at the Filariasis Chemotherapy Unit of the T. D. Medical College Hospital
in Kerala, India
- Random assignment to receive either: 400 mg albendazole and DEC 300 mg given once a
year for 2 years (standard treatment); or 800 mg albendazole and DEC 300 mg given once
a year for 2 years; or 800 mg albendazole and DEC 300 mg given twice a year for 2
years.
- Urine pregnancy test for women of childbearing age .
- Ultrasound test to look for filarial worms.
- Treatment dose.
- Monitoring for symptoms
6-month 3-day hospital stay
- Medical history, physical examination and blood test.
- Repeat ultrasound in subjects whose first ultrasound detected adult worms.
- Treatment dose for subjects receiving medicine every 6 months.
- Urine pregnancy test for women of childbearing age.
1-year 3-day hospital stay
- Medical history, physical examination and blood test.
- Treatment dose.
- Repeat ultrasound in subjects whose first ultrasound detected adult worms.
- Urine pregnancy test for women of childbearing age.
18-month 3-day hospital stay
- Medical history, physical examination and blood test.
- Treatment dose for subjects receiving medicine every 6 months.
- Urine pregnancy test for women of childbearing age.
24-month 3-day hospital stay
- Medical history, physical examination and blood test.
- Treatment dose.
- Repeat ultrasound in subjects whose first ultrasound detected adult worms.
- Urine pregnancy test for women of childbearing age.
Treatment of Asymptomatic Toxocariasis With Albendazole in Children [Recruiting]
The purpose of this study is to evaluate effectiveness of albendazole in the treatment of
the asymptomatic infection with the parasite Toxocara in children. Treatment response is
defined as a reduction in the number of eosinophils in blood. The study drug will be
compared to placebo and randomly assigned in a double blind manner. Follow up will be
prospective. 50 children (25 per group) will be enrolled in the study.
Effectiveness of Combined Albendazole and Ivermectin Treatment for Intestinal Worm Infections [Completed]
The aim of this study is to compare the efficacy and impact on growth of two drug treatments
against intestinal worms in schoolchildren from a rural area of Guatemala. According to the
World Bank, these intestinal worms are one of the top causes of childhood health problems in
many areas of the developing world (The World Bank, 1993). Infected children are more likely
to have inadequate nutrition due to the worm infections and are more likely to be shorter in
height and weigh less than children who are not infected. After collecting height and weight
information, we will split the children into two groups. One group will receive albendazole
and the other group will receive combined albendazole/ivermectin. Both groups will be
receiving albendazole, the current standard of care treatment. Ivermection is expected to
improve efficacy and nutritional benefit as well as add increased scope of treatment for the
worm Strongyloides, and ectoparasites such as scabies and head lice. Both treatment regimens
and the combination have been used millions of times in the developing world and are safe to
use. Co-administration of drugs would be a more efficient use of the opportunity to access
schoolchildren and provide deworming treatment.
Effectiveness of High-dose Zinc Therapy and Albendazole in the Treatment of Environmental Enteropathy [Not yet recruiting]
The purpose of this study is to investigate the therapeutic effectiveness of high-dose zinc
therapy and de-worming albendazole as separate interventions in restoring normal gut
absorptive and immunological function as measured by the dual sugar permeability test and
additional biomarkers in 1-3 year old rural Malawian children at high risk for Environmental
Enteropathy.
|
